Costs of human resources in delivering cancer chemotheraphy and managing chemotheraphy-induced neutropenia in community practice

Community Oncology

Volumn 1, Issue 1, 2004, Pages 23-28

  Fortner, Barry V ^a   Okon, Theodore A ^a   Zhu, Ling ^a   Tauer, Kurt ^b   Moore, Kelley ^a   Templeton, Davis ^a   Schwartzberg, Lee ^b  

^a Supportive Oncology Services Incorporated   (United States)

^b Hematology and Medical Oncology   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; COLONY STIMULATING FACTOR; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ADULT; ANEMIA; ARTICLE; CANCER CENTER; CANCER CHEMOTHERAPY; CLINICAL PROTOCOL; COMMUNITY CARE; DRUG COST; FEBRILE NEUTROPENIA; FEMALE; HEALTH CARE COST; HEALTH CARE DELIVERY; HOSPITALIZATION; HUMAN; INTERVIEW; MALE; MEDICAL PRACTICE; NEUTROPENIA; OUTPATIENT CARE; PATIENT CARE; RESOURCE ALLOCATION; RETROSPECTIVE STUDY; TIME; UNITED STATES;

EID: 13844267360     PISSN: 15485315     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1548-5315(11)70766-5     Document Type: Article

References (26)

1. Houston D. Supportive therapies for cancer chemotherapy patients and the role of the oncology nurse. Cancer Nurs 1997;20:409-413.
2. Lamkin L. Outpatient oncology settings: a variety of services. Semin Oncol Nurs 1994;10:229-236.
3. Pearce S, KeUy D, Stevens W. "More than just money"-widening the understanding of the costs involved in cancer care. J Adv Nurs 2001;33:371-379.
4. Houts PS, Lipton A, Harvey HA, et al. Nonmedical costs to patients and their families associated with outpatient chemotherapy. Cancer 1984;53:2388-2392.
5. Moore KA. Breast cancer patients' out-of-pocket expenses. Cancer Nurs 1999;22:389-396.
6. Ashley J, Taylor D, Houts A, Former B, Durrence H. The experience of chemotherapy-induced neutropenia: quality-of-life interviews with adult cancer patients. Oncol Nurs Forum 2003;30:120. Abstract 39.
7. Carelle N, Piotto E, Bellanger A, Germanaud J, Thuillier A, Khayat D. Changing patient perceptions of the side effects of cancer chemotherapy. Cancer 2002;95:155-163.
8. Cella D. The Functional Assessment of Cancer Therapy-Anemia (FACT-An) Scale: a new tool for the assessment of outcomes in cancer anemia and fatigue. Semin Hematol 1997;34(3 suppl 2):13-19.
9. Curt GA, Breitbart W, Cella D, et al. Impact of cancer-related fatigue on the lives of patients: new findings from the Fatigue Coalition. Oncologist 2000;5:353-360.
10. Yellen SB, Cella DF, Webster K, Blendowski C, Kaplan E. Measuring fatigue and other anemia-related symptoms with the Functional Assessment of Cancer Therapy (FACT) measurement system. J Pain Symptom Manage 1997;13:63-74.
11. Holmes FA, O'Shaughnessy JA, Vukelja S, et al. Blinded, randomized, multicenter study to evaluate single administration pegfilgrastim once per cycle versus daily filgrastim as an adjunct to chemotherapy in patients with high-risk stage II or stage III/IV breast cancer. J Clin Oncol 2002;20:727-731.
12. Green MD, Koelbl H, Baselga J, et al. A randomized double-blind multicenter phase III study of fixed-dose single-administration pegfilgrastim versus daily filgrastim in patients receiving myelosuppressive chemotherapy. Ann Oncol 2003;14:29-35.
13. Mucenski JW, Shogan JE. Maximizing the outcomes in cancer patients receiving chemotherapy through optimal use of colony-simulating factor. J Manag Care Pharm 2003;9(2 suppl):10-14.
14. Bonadonna G, Valagussa P, Moliterni A, Zambetti M, Brambilla C. Adjuvant cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer: the results of 20 years of follow-up. N Engl J Med 1995;332:901-906.
15. Budman DR, Berry DA, Cirrincione CT, et al. Dose and dose intensity as determinants of outcome in the adjuvant treatment of breast cancer. J Natl Cancer Inst 1998;90:1205-1211.
16. Kwak LW, Halpern J, Olshen RA, Horning SJ. Prognostic significance of actual dose intensity in diffuse large-cell lymphoma: results of a tree-structured survival analysis. J Clin Oncol 1990;8:963-977.
17. Kuderer NM, Cosier L, Crawford J, Dale DC, Lyman GH. Cost and mortality associated with febrile neutropenia in adult cancer patients. In: Program/Proceedings of the 38th Annual Meeting of the American Society of Clinical Oncology; May 18-21, 2002; Orlando, Fla. Abstract 998.
18. Lyman GH, Kuderer NM, Crawford J, Dale D. Economic impact of pegfilgrastim use based on the risk of febrile neutropenia (FN) in NHL patients treated with CHOP. In: Program/Proceedings of the 39th Annual Meeting of the American Society of Clinical Oncology; May 31-June 3, 2003; Chicago, Ill. Abstract 2384.
19. Neupogen (filgrastim) prescribing information. Thousand Oaks, Calif: Amgen; 2002.
20. Dale DC. Optimizing the management of chemotherapy-induced neutropenia. Clin Adv Hematol Oncol 2003;1:679-684.
21. Scott SD, Chrischilles EA, Link BK, Delgado DJ, Fridman M, Stolshek BS. Days of prophylactic filgrastim use to reduce febrile neutropenia in patients with non-Hodgkin's lymphoma treated with chemotherapy. J Manag Care Pharm 2003;9(2 suppl):15-21.
22. Crawford J, Dale DC, Lyman GH. Chemotherapy-induced neutropenia: risks, consequences, and new directions for its management. Cancer 2004;100:228-237.
23. Glynn-Tucker EM. A multidisciplinary performance improvement project for the management of febrile neutropenia. Oncol Nurs Forum 2002;29:354. Abstract 97.
24. Maxwell C, Winkler L, Lottenberg M. Nurse driven neutropenia management guidelines: improving patient outcomes through evidence-based practice. Oncol Nurs Forum 2002;29:371. Abstract 171.
25. Anastasia PJ, Blevins MC. Outpatient chemotherapy: telephone triage for symptom management. Oncol Nurs Forum 1997;24(1 suppl):13-22.
26. Lindley C, Vasa S, Sawyer WT, Winer EP. Quality of life and preferences for treatment following systemic adjuvant therapy for early-stage breast cancer. J Clin Oncol 1998;16:1380-1387.